Evexta Bio and Roche Partner to Evaluate Rupitasertib Combination in Advanced Breast Cancer
PARIS, Aug. 4, 2026 Evexta Bio announced a clinical trial collaboration and supply agreement with Roche to evaluate its...
giredestrant
Advertisement
Roche’s Giredestrant NDA Accepted by FDA for Early Breast Cancer
BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
FDA Accepts Genentech NDA for Giredestrant in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif., June 1, 2026 Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted...
Genentech Highlights Giredestrant Data at ASCO 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...
Phase III Study Shows Giredestrant Boosts Breast Cancer Survival
Basel, Switzerland — September 22, 2025 — Positive phase III trial results from the evERA study reveal that the...
Advertisement
